Alan Davidson

Dr. Alan Davidson


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2011 in Nature
Verified
Journal Article
Closed access
PDF file
CDCuong Q. Diep
Cuong Q. Diep
DMDongdong Ma
Dongdong Ma
RDRahul C. Deo
Rahul C. Deo
THTeresa M. Holm
Teresa M. Holm
RNRichard W. Naylor
Richard W. Naylor
ADAlan Davidson
Alan Davidson

1 August 2018 in Stem Cell Reports
Verified
Journal Article
Open access
APAneta Przepiorski
Aneta Przepiorski
VSVeronika Sander
Veronika Sander
TTTracy Tran
Tracy Tran
JHJennifer A. Hollywood
Jennifer A. Hollywood
BSBrie Sorrenson
Brie Sorrenson
ADAlan Davidson
Alan Davidson
Kidney organoids made from pluripotent stem cells have the potential to revolutionize how kidney development, disease, and injury are studied. Current protocols are technically complex, suffer from poor reproducibility, and have high reagent costs that restrict scalability. To overcome some of these issues, we have established a simple, inexpensive, and robust method to grow kidney organoids in bulk from human induced pluripotent stem cells. Our organoids develop tubular structures by day 8 and show optimal tissue morphology at day 14. A comparison with fetal human kidneys suggests that day-14 organoid tissue most closely resembles late capillary loop stage nephrons. We show that deletion of HNF1B, a transcription factor linked to congenital kidney defects, interferes with tubulogenesis, validating our experimental system for studying renal developmental biology. Taken together, our protocol provides a fast, efficient, and cost-effective method for generating large quantities of human fetal kidney tissue, enabling the study of normal and aberrant kidney development.

14 July 2011 in Developmental Dynamics
Verified
Journal Article
Open access
PDF file
Rebecca WingertRebecca Wingert
Rebecca Wingert
ADAlan Davidson
Alan Davidson
Kidney nephrons are composed of proximal and distal tubule segments that perform unique roles in excretion. The developmental pathways that establish nephron segment identities from renal progenitors are poorly understood. Here, we used the zebrafish pronephros to study nephron segmentation. We found that zebrafish nephron progenitors undergo elaborate spatiotemporal expression changes of many genes before adopting a segment fate. Initially, two domains of nephron progenitors are established, then are subdivided and demarcate individual nephron segments. Using genetic and chemical genetic models of retinoic acid (RA) deficiency, we discovered that RA modulates rostral progenitor formation. To delineate downstream pathways, we knocked down the irx3b transcription factor and found it regulates proximal tubule segment size and distal segment differentiation. Our results suggest a model whereby RA patterns the early field of nephron progenitors, with subsequent factors like irx3b acting to refine later progenitor subdomains and ensure activation of segment‐specific gene programs. Developmental Dynamics 240:2011–2027, 2011.

1 January 2013 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
RNRichard W. Naylor
Richard W. Naylor
APAneta Przepiorski
Aneta Przepiorski
QRQun Ren
Qun Ren
JYJing Yu
Jing Yu
ADAlan Davidson
Alan Davidson
Nephrons comprise a blood filter and an epithelial tubule that is subdivided into proximal and distal segments, but what directs this patterning during kidney organogenesis is not well understood. Using zebrafish, we found that the HNF1β paralogues hnf1ba and hnf1bb, which encode homeodomain transcription factors, are essential for normal segmentation of nephrons. Embryos deficient in hnf1ba and hnf1bb did not express proximal and distal segment markers, yet still developed an epithelial tubule. Initiating hnf1ba/b expression required Pax2a and Pax8, but hnf1ba/b-deficient embryos did not exhibit the expected downregulation of pax2a and pax8 at later stages of development, suggesting complex regulatory loops involving these molecules. Embryos deficient in hnf1ba/b also did not express the irx3b transcription factor, which is responsible for differentiation of the first distal tubule segment. Reciprocally, embryos deficient in irx3b exhibited downregulation of hnf1ba/b transcripts in the distal early segment, suggesting a segment-specific regulatory circuit. Deficiency of hnf1ba/b also led to ectopic expansion of podocytes into the proximal tubule domain. Epistasis experiments showed that the formation of podocytes required wt1a, which encodes the Wilms’ tumor suppressor-1 transcription factor, and rbpj, which encodes a mediator of canonical Notch signaling, downstream or parallel to hnf1ba/b. Taken together, these results suggest that Hnf1β factors are essential for normal segmentation of nephrons during kidney organogenesis.

1 October 2011 in Developmental Biology
Verified
Journal Article
Closed access
LOLori L. O'BRien
Lori L. O'BRien
MGMichael Grimaldi
Michael Grimaldi
ZKZachary Kostun
Zachary Kostun
Rebecca WingertRebecca Wingert
Rebecca Wingert
RSRori Selleck
Rori Selleck
ADAlan Davidson
Alan Davidson

20 March 2020 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
JHJennifer Anne Hollywood
Jennifer Anne Hollywood
APAneta Przepiorski
Aneta Przepiorski
RDRandall F. D’sOuza
Randall F. D’sOuza
SSSreevalsan Sreebhavan
Sreevalsan Sreebhavan
EWErnst J. Wolvetang
Ernst J. Wolvetang
THTeresa M. Holm
Teresa M. Holm
Significance Statement: In its severest form, the lysosomal storage disease cystinosis is characterized by accumulation of cystine; renal proximal tubule dysfunction; and kidney failure. Research has also implicated cystinosin in modulating the mammalian target of rapamycin (mTOR) complex 1 pathway. Use of the cystine-depleting drug cysteamine, the sole treatment option for cystinosis, only slows disease progression. The authors developed induced pluripotent stem cell and kidney organoid models of cystinosis that exhibit elevated cystine levels, enlarged lysosomes, increased apoptosis, and defective basal autophagy. Although the latter is not rescued by cysteamine treatment, mTOR inhibition with everolimus was able to restore basal autophagy to levels of healthy controls. Dual treatment of everolimus and cysteamine rescued all of the observed cystinotic phenotypes in the models, suggesting that a combination therapy may improve outcomes in patients with cystinosis.Background: Mutations inCTNS—a gene encoding the cystine transporter cystinosin—cause the rare, autosomal, recessive, lysosomal-storage disease cystinosis. Research has also implicated cystinosin in modulating the mTORC1 pathway, which serves as a core regulator of cellular metabolism, proliferation, survival, and autophagy. In its severest form, cystinosis is characterized by cystine accumulation, renal proximal tubule dysfunction, and kidney failure. Because treatment with the cystine-depleting drug cysteamine only slows disease progression, there is an urgent need for better treatments.Methods: To address a lack of good human-based cell culture models for studying cystinosis, we generated the first human induced pluripotent stem cell (iPSC) and kidney organoid models of the disorder. We used a variety of techniques to examine hallmarks of cystinosis—including cystine accumulation, lysosome size, the autophagy pathway, and apoptosis—and performed RNA sequencing on isogenic lines to identify differentially expressed genes in the cystinosis models compared with controls.Results: Compared with controls, these cystinosis models exhibit elevated cystine levels, increased apoptosis, and defective basal autophagy. Cysteamine treatment ameliorates this phenotype, except for abnormalities in apoptosis and basal autophagy. We found that treatment with everolimus, an inhibitor of the mTOR pathway, reduces the number of large lysosomes, decreases apoptosis, and activates autophagy, but it does not rescue the defect in cystine loading. However, dual treatment of cystinotic iPSCs or kidney organoids with cysteamine and everolimus corrects all of the observed phenotypic abnormalities.Conclusions: These observations suggest that combination therapy with a cystine-depleting drug such as cysteamine and an mTOR pathway inhibitor such as everolimus has potential to improve treatment of cystinosis.